Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Operating Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Operating Expenses for 15 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 11.87% to $5.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.7 million, a 8.17% decrease, with the full-year FY2024 number at $20.5 million, up 12.53% from a year prior.
  • Operating Expenses was $5.9 million for Q3 2025 at Plus Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $5.9 million in Q3 2025 to a low of $2.5 million in Q1 2021.
  • A 5-year average of $4.5 million and a median of $5.0 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 150.64% in 2021, then crashed 41.16% in 2025.
  • Plus Therapeutics' Operating Expenses stood at $3.5 million in 2021, then skyrocketed by 63.56% to $5.7 million in 2022, then dropped by 9.65% to $5.2 million in 2023, then increased by 2.73% to $5.3 million in 2024, then grew by 10.67% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Operating Expenses are $5.9 million (Q3 2025), $2.9 million (Q2 2025), and $4.6 million (Q1 2025).